Edition:
United States

Alimera Sciences Inc (ALIM.O)

ALIM.O on Consolidated Issue listed on NASDAQ Global Market

1.49USD
30 Sep 2016
Change (% chg)

-- (+0.00%)
Prev Close
$1.49
Open
$1.50
Day's High
$1.54
Day's Low
$1.44
Volume
574,762
Avg. Vol
750,712
52-wk High
$5.15
52-wk Low
$1.01

Latest Key Developments (Source: Significant Developments)

Great point reports 5.12 pct passive stake in Alimera Sciences - SEC filing
Monday, 22 Aug 2016 04:41pm EDT 

Alimera Sciences Inc :Great Point Partners Llc reports 5.12 percent passive stake in alimera sciences inc as of Aug. 11 - sec filing.  Full Article

Alimera Sciences prices public offering of common stock
Thursday, 11 Aug 2016 08:41am EDT 

Alimera Sciences Inc : Alimera Sciences prices public offering of common stock .Says public offering of 18.0 million common shares priced at $1.40per share.  Full Article

Alimera Sciences proposes public offering of common stock
Wednesday, 10 Aug 2016 04:01pm EDT 

Alimera Sciences Inc : Alimera Sciences proposes public offering of common stock .All shares in offering are to be sold by Alimera, with net proceeds to be used to fund continued commercialization of Iluvien.  Full Article

Alimera Sciences Q2 GAAP loss per share $0.15
Wednesday, 3 Aug 2016 05:41pm EDT 

Alimera Sciences Inc : Alimera sciences announces second quarter 2016 financial results and provides business update . Q2 gaap loss per share $0.15 . Q2 adjusted non-gaap loss per share $0.17 . Q2 revenue rose 66 percent to $9.6 million . Alimera sciences inc says has engaged in discussions with fda regarding potential future indications for iluvien .Based on discussions, believes it should be able to establish adequate evidence of safety and efficacy for approval of iluvien for additional indication.  Full Article

Alimera Sciences sees Q2 revenue of $9.3 mln - $9.5 mln
Tuesday, 26 Jul 2016 07:30am EDT 

Alimera Sciences Inc: Announces record second quarter 2016 revenue . Sees Q2 2016 revenue $9.3 million to $9.5 million . Says modified liquidity and revenue covenants in its existing loan agreement with Hercules Capital Inc . Says modification allows for reduction of Alimera's liquidity threshold . Q2 revenue view $7.2 million -- Thomson Reuters I/B/E/S . Says modifies its liquidity and revenue covenants under its loan facility . Says Q2 2016 u.s. Revenue is expected to be in range of $7.0 million to $7.2 million .Says modification reduces Co's trailing three-month revenue requirement through period ending August 31, 2016.  Full Article

Alimera Sciences signs Knight Therapeutics as distributor for Canada
Tuesday, 21 Jul 2015 07:30am EDT 

Alimera Sciences Inc:Says signs Knight Therapeutics as exclusive iluvien® distributor for Canada.Says Knight will also handle all regulatory and commercial activities for iluvien in Canada.  Full Article

Alimera Sciences Inc's ILUVIEN receives 17th european marketing authorization
Tuesday, 14 Apr 2015 08:00am EDT 

Alimera Sciences Inc:Says that marketing authorization has been granted by Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to ILUVIEN.For treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.Polish approval marks 17thand final country authorization to be granted through the European Repeat-Use application procedure.  Full Article

Alimera Sciences announces closing of $50.0 mln financing with Deerfield Management
Monday, 15 Dec 2014 08:45am EST 

Alimera Sciences:Closes its offering of Series B Preferred Stock with Deerfield Management and certain of its affiliates (Deerfield).Alimera issued Deerfield an aggregate of 8,291.873 shares of Series B Preferred Stock for a purchase price of $6,030.00 per share, or an aggregate purchase price of about $50 mln.Alimera also issued an additional 124.378 shares of Series B Preferred Stock to Deerfield as a subscription premium.Plans to use proceeds for commercial launch of its lead product, ILUVIEN, in the United States, continued marketing efforts in Europe and general corporate purposes.  Full Article

Alimera Sciences' ILUVIEN receives marketing authorization in Ireland for treatment of chronic diabetic macular edema
Monday, 17 Nov 2014 11:45am EST 

Alimera Sciences Inc:Says the Irish Health Products Regulatory Authority (HPRA) has granted marketing authorization to ILUVIEN for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.Approval marks the fifth European approval through the Repeat-Use application procedure and the 13thapproval worldwide for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).ILUVIEN is now approved for marketing in Austria, Belgium, Denmark, France, Germany, Ireland, Italy, Norway, Portugal, Spain, Sweden, the United Kingdom and the United States, and is commercially available in the United Kingdom and Germany.ILUVIEN is pending approval in an additional five European Union (EU) countries included in the Repeat-Use application procedure.  Full Article

Alimera Sciences Inc's ILUVIEN receives marketing authorization in Belgium for treatment of chronic diabetic macular edema
Wednesday, 12 Nov 2014 07:30am EST 

Alimera Sciences Inc:Says Belgian Federal Agency for Medicines and Health Products (FAMHP) has granted marketing authorization to ILUVIEN.For treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.  Full Article

BRIEF-Great point reports 5.12 pct passive stake in Alimera Sciences - SEC filing

* Great Point Partners Llc reports 5.12 percent passive stake in alimera sciences inc as of Aug. 11 - sec filing Source text for Eikon: Further company coverage: